Introduction
The antigenic structure of poliovirus has been studied by the isolation of antigenic variants resistant to neutralization by monoclonal antibodies (MAbs) and at least four distinct sites have been defined to which neutralizing antibodies may attach (Minor et al., 1983 Diamond et al., 1985; Blondel et al., 1986; Page et al., 1988; Wiegers et al., 1989) . The sites form distinct structures on the surface of the virion (Hogle et al., 1985; Filman et al., 1989) , one of which assembles around the pentameric apex of the virion. This site, currently designated site 1, is composed of amino acid residues from four loops from the virion protein VP1, which include residues 89 to 100, 142 and 143, 166 and 253 in the poliovirus type 3 numbering system Wiegers et al., 1989; M. Ferguson, unpublished results) .
The availability of full-length infectious clones of poliovirus DNA makes it possible to alter specific regions of the virus relatively easily by established methods of recombinant DNA technology (Burke et al., 1988 Murray et al., 1988a) . Several groups of workers have reported the preparation of antigenic chimeras of poliovirus which express dual antigenicity (Burke et al., 1988; Murray et al., 1988a; Murdin & Wimmer, 1989) . Foreign and synthetic epitopes have been expressed also (Colbere-Garapin et al., 1988; Evans et al., 1989; Jenkins et al., 1990) .
Chimeras in which the main loop of site 1 of the mouse-adapted Lansing strain of type 2 poliovirus was inserted into the equivalent site of the type 1 strain Mahoney have been reported and render the virus able to replicate in mice (Murray et al., 1988b; Martin et al., 1988) .
This communication describes chimeric viruses based on the Sabin type 1 strain in which portions of the sequence encoding site 1 were replaced with variations of the corresponding regions of the Sabin type 3 strain. The degree to which the sites were functionally expressed was analysed serologically using polyclonal antibodies and MAbs against poliovirus, antipeptide sera and the induction of antibodies in a range of animals. Although the site was generally only partly functional antigenically, the results provide an insight into the antigenic and immunogenic properties of the site in the native virus. The findings also suggest ways in which the fidelity of the antigenic exchange can be improved.
Methods
Construction of chimeric viruses. The construction and recovery of infectious virus S1/3-10 has been described previously (Burke et al., 1988) . Chimeras S1/3-11, S1/3-10-2 and S1/3-11-3 were constructed in an analogous manner using gapped duplex oligonucleotide-directed 
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mutagenesis. SI/3-T and S1/3-11-2 were constructed by ligation of complementary oligonucleotides to the mutagenesis cassette vector pCASI . Recovery of virus was achieved following transfection of Hep2c cells with RNA transcripts, which were derived in vitro from modified eDNA by virtue of a T7 polymerase promoter engineered at the 5' end of the eDNA. The construction of the recombinant pOT5 has been described previously (Stanway et al., 1986) . Although reported as unable to give rise to infectious virus upon transfection, the engineering of a T7 polymerase promoter at the 5' end of pOT5 resulted in the production of infectious RNA transcripts. Viruses were recovered by transfection of Hep2c cells (Burke et al., 1988 and the sequence of the inserted sequence was determined by dideoxynucleotide sequencing of the appropriate region of the genomic RNA .
Neutralization of viruses.
The virus to be assayed was incubated alone or with a 1 : 200 dilution of a monospecific type 1 serum from guineapigs, a l : 20 dilution of a monospecific type 2 serum from monkeys, or a 1 : 200 dilution of a monospecific type 3 serum from monkeys for 3 h at 35 °C, before residual virus was assayed by a standard TCIDso method (Domok & Magrath, 1979) . Results, i.e. the reduction in titre, were expressed as log10 TCID50 in the presence of antibody. The neutralization of the virus by MAbs was measured by standard microtitre methods using a constant challenge of virus, and the results were expressed as endpoint dilution titres (Domok & Magrath, 1979) .
Antigen-blocking tests. Single radial immunodiffusion (SRD) antigenblocking tests were performed as described (Ferguson et al., 1984) .
Antipeptide sera. A peptide of 18 amino acids corresponding to a region of VP1 of type 3 from amino acids 89 to 104 with additional Cand N-terminal cysteine residues (Cambridge Research Biochemicals) was conjugated to keyhole limpet haemocyanin or bovine thyroglobulin with glutaraldehyde and used to immunize rabbits as described previously .
Immunization of animals. Rabbits were immunized with 0-5 ml of sucrose-purified virus in Freund's adjuvant. Three doses were given 3 weeks apart by the intramuscular route. MAbs were generated in mice as described in Ferguson et al. (1984) and screened by SRD antigenblocking tests.
Results

Structure of chimeric viruses
All viruses recovered from chimeric constructs were shown to be neutralized by a pool of human serum samples from the U.K. Infection was shown to be prevented by a MAb specific for the poliovirus receptor on susceptible cells . The chimeras thus behaved serologically as polioviruses, and were handled under the corresponding containment conditions. The seven viruses examined are shown in Table 1 . One virus, designated pot 5, was derived from a construct previously thought incapable of giving viable virus (Stanway et al., 1986) in which a 76 amino acid sequence from residues 74 to 149 (type 1 numbering) was exchanged between type 1 and type 3. This region includes residues 142 and 143 which are also implicated in site 1. The sequence of the RNA of the virus is being studied to identify possible genomic differences from the original DNA plasmid which could account for its viability.
The six other viruses studied had exchanged segments restricted to amino acids 89 to 100 in the type 3 numbering (91 to 102 in the type 1 numbering). Virus S1/3-11-3 contained the complete sequence of type 3 from amino acids 89 to 100 inserted into the corresponding region of the Sabin 1 sequence, whereas S1/3-11-2 retained the threonine residue found at the N terminus of this sequence in type 1. Virus S1/3-11 was a similar construct in which the amino acid at position 89 was an isoleucine, rather than a threonine as in Sabin 1 or a glutamic acid as in Sabin 3. Construct S1/3-10-2 contained an arginine in place of the proline at residue 95 and a valine in place of the alanine at residue 99, while $1/3T-contained a threonine instead of a glutamic acid at residue 89, and an asparagine instead of an arginine at residue 98. Both S1/3-10-2 and S1/3T-had inserted segments which were modified in amino acids considered to be antigenically highly significant in the type 3 strain of poliovirus . Construct S1/3-10 contains a threonine at residue 89 and a valine in place of the alanine at residue 99. Some of the properties of S1/3-10 have been described previously (Burke et al., 1988) . 
Reactions with monospecific sera
The ability of monospecific sera to neutralize the chimeras was examined by measuring the drop in titre observed at a single serum dilution. The results are summarized in Table 2 . At the dilutions used the sera were able to reduce the titre of the Sabin strains of type 1, type 2 or type 3 poliovirus by at least 7 loglo TCIDso units (data not shown). All chimeric viruses were completely neutralized by the type l-specific serum, but no virus was affected by the type 2-specific serum. The type 3-specific serum reduced the titre of five of the seven chimeras by 3-6 to 4.0 loglo TCIDso. The properties of the non-neutralized fraction are currently being examined to establish whether they are antigenic variants. The two viruses which were not significantly neutralized by the monospecific type 3 serum were S1/3-10-2 and SI/3T-.
Reactions with MAbs
Panels of MAbs specific for type 1 or for type 3 have been prepared, and the sites each antibody recognizes have been established by their reaction with antigenic mutants (Minor et al., 1983 (Minor et al., , 1987 M. Ferguson, unpublished results ). All seven chimeras described here failed to react with MAbs specific for site 1 of type 1, while reacting with antibodies against all other sites on type 1 (data not shown). This supports the view that site 1 is independent of the other antigenic structures on the virus surface. Similarly the chimeras did not react with MAbs specific for sites on poliovirus type 3 other than site 1 (data not shown).
The reactions of the chimeras with 18 antibodies specific for site 1 of type 3 poliovirus were determined by antigen-blocking tests, and the results are shown in Table  3 (a).
This method measures the binding of the antibody to the virus independent of any biological effect such as neutralization. Where a reaction occurred, the titre of an antibody when tested with a particular chimera was often less than its titre when tested with the Sabin type 3 strain, indicating that the presentation of the epitope was imperfect. Of the five antibodies which reacted with chimera S1/3-10-2 only 472 reacted to the same titre as with Sabin 3, which expresses the site in native form. Only two antibodies bound to SI/3T-and did so to a lower titre than to Sabin 3. This is consistent with the reactions with the type 3-specific polyclonal sera which recognized these viruses poorly. Chimera S1/3-10 was recognized less readily than the Sabin 3 strain by all except antibodies 25-4-12 and 25-1-14, although it reacted to some extent with seven antibodies. Chimeras S1/3-11, S1/3-11-2 and S1/3-11-3 differ at the amino acid corresponding to residue 89 of type 3, which is a threonine in S1/3-11-2, as in the type 1 Sabin strain, a glutamic acid in S1/3-11-3 as in Sabin 3, and an isoleucine in S/3-11. Chimera S1/3-11-2 was recognized by 11 of the 18 antibodies, S1/3-11 by 10 and S1/3-11-3 by eight. In addition nine of the 11 reacting antibodies reacted to the same titre with S1/3-11-2 as with the Sabin type 3 strain. In contrast only three of the eight reacting antibodies reacted to the same titre with S1/3-11-3 and the Sabin type 3 strain. Therefore, retaining the type 1 residue at amino acid 89 improved the recognition by type 3 antibodies, although the glutamic acid at this position is implicated in the type 3 site as shown below. This may imply that the amino acid at residue 89 has a significant effect on the conformation of the site rather than being involved in the epitopes of the antibodies per se.
Pot 5, in which the substituted fragment was far larger than in the other chimeras, reacted with 13 of the 18 antibodies, 10 of which had the same titre against pot 5 as against the Sabin type 3 strain. Therefore, of the chimeras examined, pot 5 expressed the site most accurately.
Whereas many of the viruses reacted in the antigenblocking assay, fewer reacted in neutralization tests (Table 3b ). In particular S1/3T-was not neutralized by any antibody and S1/3-11-3 in which the sequence of type 3 from residues 89 to 100 of VP1 was correctly inserted, was consistently neutralized only by antibody 472. This was also true of six plaques picked from S1/3-11-3, demonstrating that it was not an artefact of a mixed population although in some tests there appeared to be partial neutralization by antibody 204 (data not shown). Moreover S1/3-11 was neutralized by six antibodies, five having comparable titres against S1/3-11 and Sabin 3, while S1/3-11-2 was neutralized by four, of which only 472 neutralized it to a titre comparable to that against Sabin 3. This contrasts with the results obtained in blocking tests which suggested that S1/3-11-2 presented the antigenic site rather more accurately than S1/3-11. The chimeras generally presented the site less well in For example antibody 438 bound to S1/3-11-3 and to the Sabin type 3 strain to the same titre (Table 3a) , but did not neutralize S1/3-11-3 at all (Table 3b) . For pot 5, however, binding followed neutralization, the exceptions being 442, which neutralized pot 5 but not the Sabin 3 strain~and 471, which neutralized the Sabin 3 strain but not pot 5. The chimeras may prove useful tools in studying the structural basis of neutralization. The amino acid substitutions in the type 3 sequence which affected the binding of the MAbs could be deduced from the reactivity of the 18 antibodies shown in Table 3 in neutralization tests with 23 mutants with known single amino acid substitutions within site 1 ( Minor et al., 1985) . The results are summarized in Table   4 where a plus sign indicates that reaction of the antibody is affected by the substitution. Eleven of the 19 antibodies failed to react with a mutant in which the alanine at residue 99 of the VP1 of type 3 was replaced by a valine. Therefore it would be predicted that these antibodies, which included 520, 175, 438, 442, 471, 194, 165, 197, 208, 199 and 441, should not react with either S1/3-10 or S1/3-10-2 which have a valine residue at this position. Two mutants possessed substitutions at residue 89 of the VP1 of type 3, in which a glutamic acid was replaced by a lysine or a glycine respectively. Mutants in which the glutamic acid was replaced by either isoleucine or threonine were not isolated so the reactions of the antibodies with chimeras S1/3-10-2, S1-3T-, S1/3-10, S1/3-11 or S1/3-11-2 could not be predicted with confidence. However antibodies 471, 165, 208, 199 and 441 were affected by either substitution found in the mutants, and were therefore considered to be strongly affected by the amino acid at position 89. They were thus not expected to react with chimeras containing any residue other than a glutamate at this position. Anti:
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bodies 472, 197 and 134 were affected by one substitution but not the other.
In one mutant the proline residue at position 95 was replaced by a leucine and this affected the reactions of antibodies 520, 471,197, 208, 134, 441 and 27-4-4 . These antibodies might be affected by the replacement of the proline residue with an arginine in chimera S1/3-10-2.
Finally none of the three mutants in which the arginine at residue 98 was substituted reacted with antibodies 472, 204, 438, 442, 471,194, 165, 197, 199, 441, 25-1-14, 25-4-12 or 27-4-4, and these antibodies would be expected not to react with S1/3T-. The precise substitution of an asparagine for the arginine residue 98 was not found in any of the mutants however. Antibodies 495, 520, 175, 208 and 134 were affected by either one or two of the substitutions found in the three mutants isolated. Table 5 .
Reactions of antipeptide sera with chimeras in antigen-blocking tests
Rabbit serum Sabin 3 S1/3-10-2 S1/3-T-S1/3-10 S1/3-11 S1/3-11-2 S1/3-11-3 pot 5 77 >320 > 320 40 > 320 320 >320 >320 > 320 78 >320 < 10 320 >320 >320 >320 >320 >320 98 >320 < 10 80 >320 320 >320 >320 160 120 > 320 < 10 40 < 10 320 320 >320 >320 121 > 320 < 10 < 10 80 160 >320 320 >320 160 > 320 < 10 < 10 < 10 < 10 40 10 >320
From the reactivity of antibodies of mutants described above it was possible to predict which of the antibodies would fail to react with a particular chimera, either because the exact substitution was known to be present in a mutant, as in the alanine to valine substitution at residue 99, or because no known substitution was tolerated in a particular position, as for the glutamate at residue 89, the proline at residue 95 and the arginine at residue 98. The results are summarized in Table 3 (c).
There were major discrepancies between the predicted reactions in Table 3 (c) and the observed reactions in neutralization tests shown in Table 3 (b). For example antibody 495 neutralized only S1/3-11 and pot 5, although being predicted to neutralize all seven constructs. Similarly construct S1/3-11-3 was neutralized only by antibody 472, although predicted to be neutralized by 18 antibodies. Numerous other examples are evident from a comparison of Tables 3 (b) and 3 (c), and only antibody 472 behaved in the manner predicted.
However the reactions in antigen-blocking tests were more in keeping with those predicted, although there were still several discrepancies. For example chimera S 1/3-11-3 failed to react with a number of antibodies, and antibodies 134 and 441 failed to recognize any chimera. Conversely antibody 520 both bound to and neutralized S1/3-10, although it would be predicted not to do so. Antibody 438 is predicted not to neutralize S 1/3-10-2 and antibody 471 is predicted not to neutralize S1/3-11 or S1/3-11-2. The antibodies did not neutralize the chimeras, but they did bind to them at a reduced titre.
Reactions with antipeptide sera
The amino acid sequence of peptide S 10a corresponds to residues 89 to 104 of VP1 of the Sabin type 3 strain of poliovirus with additional N-and C-terminal cysteine residues. Rabbits immunized with peptide S10a, conjugated to keyhole limpet haemocyanin or bovine thyroglobulin, developed antibodies to type 3 poliovirus . Table 5 shows the reaction in antigenblocking tests of sera from six rabbits with the chimeras and the Sabin type 3 strain itself. The titres against the Sabin type 3 strain were high in all cases. The reactions of S1/3-11, $1/3-11-2 and $1/3-11-3 were similar and differed from those of the Sabin 3 strain only for rabbit 160, which did not react with the chimeras to high titre. This suggested that except for the serum from rabbit 160 the antibodies were recognizing a sequence excluding the amino acid corresponding to residue 89 of the VP1 of type 3 at which the chimeras differed. Three other chimeras S1/3-10-2, S1/3-T-and S1/3-10 reacted less well, consistent with the presence of sequence differences between them and the Sabin type 3 strain of poliovirus. Similar findings have been obtained on the reaction of the sera with defined mutants . The remaining chimera, pot 5, reacted with all antipeptide sera to high titre.
Induction of antibodies by chimeras
Rabbits were immunized with S1/3T-, S1/3-10, S1/3-11-2 and pot 5 and the sera were examined for their ability to react with the immunizing virus or with the Sabin type 3 strain. Similar titres were observed in neutralization or antigen-blocking tests, and the results of the latter are shown in Table 6 . Antibody was induced against the immunizing virus in all cases. The highest titres of antibody against the Sabin type 3 strain were induced by pot 5, and were comparable to the titres induced against the immunizing strain. Although the titres of antibody against the Sabin type 3 strain were relatively lower for S1/3-11 and S1/3-11-2 than for pot 5, they were still significant relative to the titre against the immunizing virus. The remaining two chimeras S1/3-10 and S1/3-Tinduced lower levels of antibody against the Sabin type 3 strain. This could be due to failure to induce antibodies to the inserted sequence, or to the induction of strainspecific antibodies which recognize the inserted sequence but not the corresponding region of the Sabin type 3 strain. Similar results were obtained on immunizing guinea-pigs (data not shown).
Induction of MAbs by S1/3-10
Mice were immunized with purified S1/3-10 by either the intraperitoneal route or intrasplenic route and hybridomas were prepared as described (Ferguson et al., 1984; Minor et al., 1987) . The fusions were screened with S1/3-10 and the Sabin type 1 strain of poliovirus and the results are summarized in Table 7 . Thirty hybridomas recognizing S1/3-10 were identified in the fusion following intraperitoneal injection, of which 20 reacted with the Sabin type 1 strain, and were therefore directed against sites present on both viruses. The remaining 10 antibodies were specific for S1/3-10 and were therefore assigned to site 1, the only site at which S1/3-10 and the Sabin 1 strain differ. In contrast 17 out of 25 antibodies raised following intrasplenic injection were specific for S1/3-10 and thus against site 1. The inserted sequence was more immunogenic following intraperitoneal injection than has been previously found for site 1 of type 1 strains Diamond et al., 1985) a!though less so than site 1 of type 3. The intrasplenic route of inoculation greatly increased the number of antibodies found against the inserted sequence, as expected . Some of the antibodies assigned to site 1 of S1/3-10 were examined for reaction with the Sabin type 3 strain, and a mutant designated 370, which like S1/3-10 had a valine in place of-the aianine at residue 99 (Table 4) . The results are summarized in Table 8 . Of five site 1-specific antibodies produced by intraperitoneal immunization, three reacted with the Sabin strain of type 3 poliovirus while four reacted with 370. Of 11 site 1-specific antibodies produced by intrasplenic immunization, only one reacted with the Sabin 3 strain while three reacted with 370. More antibodies therefore reacted with the virus closer in sequence to the immunizing strain. A significant proportion of the antibodies were specific for the sequence and conformation present only in the immunizing strain.
Discussion
The results described here confirm and extend those previously reported for antigenic chimeras based on type 1 poliovirus in which part of the site 1-encoding sequence has been replaced by sequences found in type 3 poliovirus (Burke et al., 1988; Murray et al., 1988a) . The inserted sequences behaved to some degree as functionally active antigenic sites of type 3 poliovirus. When the sequence corresponding to the main component of site 1 was exchanged accurately, it was only partially functional as an antigenic site of type 3. A larger insert, in pot 5, was more effective, implying that factors in addition to the main structural component of the site play a role. These may include the presence of other less important components of the site, or effects on the conformation of the site brought about by other amino acid differences. The chimeras were usually recognized by polyclonal monospecific type 3 sera and MAbs and were able to induce both polyclonal antibodies and MAbs reacting with type 3 polioviruses. The production of MAbs against the inserted sequences was achieved more readily for the chimeric viruses than for site 1 of type 1 poliovirus and suggests a simple effective method for the production of MAbs against defined amino acid sequences in a constrained conformation. This method has been exploited for the production of MAbs against human immunodeficiency virus (HIV) sequences .
Sera raised against chemically synthesized peptides corresponding to site 1 of type 3 virus reacted well with the same sequence inserted into the chimera. Moreover when a synthetic peptide can be used to raise antibodies which recognize the native epitope, the epitope can probably be presented successfully in the form of a chimeric poliovirus. This is the case for site 1 of type 3 poliovirus as described here and previously (Burke et al., 1988; Ferguson et al., 1985) and for epitopes from HIV , papillomavirus (Jenkins et al., 1990) and chlamydia (Baehr et al., 1988; K. Burke, unpublished results) . Conversely epitopes which cannot be presented as linear peptides have not generally been presented successfully as chimeric polioviruses.
In those instances where the inserted sequence differed from that of type 3 the chimera reacted less well as a type 3 antigen in its reactions with polyclonal antibodies or MAbs and antipeptide antibodies, and in its ability to induce antibodies. To some extent the failure of a MAb to bind to the virus in antigen-blocking tests could be predicted from its reaction with defined mutants of the Sabin 3 strain. However, the predicted pattern differed radically from that observed in neutralization tests. Previous studies of the reactions of MAbs directed against site 1 of type 3 poliovirus with defined mutants have suggested that neutralization and binding were affected together (Minor et al., 1983) . This is not necessarily true of other sites (Blondel et al., 1986) , which implies that it may not be valid to assume that all of the amino acids affecting binding are contact residues. Antibody binding and neutralization are also not invariably related for the chimeric viruses. The observation that an antibody fails to neutralize the chimera although binding to the same titre as to the Sabin strain may imply that there are conformational considerations in the neutralization of virus infectivity as proposed by Mosser & Rueckert (1987) for rhinovirus. Chimeric viruses may be of value in examining this phenomenon.
There is direct evidence from the production of MAbs, and less direct evidence from the production of polyclonal antibodies that the specificity of the antibodies induced by the virus depended on the virus sequence which induced them. A proportion of the antibodies were highly strain-specific. It may therefore be possible to identify the virus which caused a particular individual to seroconvert by examining the reaction of serum with an antigenic chimera expressing a particular strainspecific site. The advantage of a chimera over a synthetic peptide in such an assay is that the chimeric sequence will be held in a constrained conformation, which may be shown as correct by the use of MAbs as described here. The conformation of the synthetic peptide is largely unknown and in our hands frequently unlike that of the native epitope . The chimera may therefore be shown to detect antibodies with a biological effect, in contrast to many synthetic peptides. The identification of the strain inducing immunity would be valuable epidemiologicaUy, for example to assess the effectiveness with which a vaccination campaign induced antibodies in recipients over and above those induced by exposure to wild-type virus.
Although the failure of MAbs to react with particular chimeras was partially predictable, a significant proportion which were predicted to react failed to do so. Therefore structures in addition to the sequence from amino acids 89 to 100 of VP1 contribute to the antigenic site, either directly or by affecting its conformation. By all criteria used, the chimera designated pot 5 was the most active of the seven examined and included type 3 amino acids at residues 142 and 143 of VP1, which are known to be implicated in site 1. It also includes other differences between type 1 and type 3, including those at residues 76, 106, 107 and 109 in the type 1 numbering. The insertion of the changes at residues 142 and 143 into chimera S1/3-11-3 is currently under way to establish whether they are sufficient to generate the antigenic structure found in pot 5.
In addition to the potential for expressing foreign epitopes and the use of chimeras in epidemiological studies the availability of antigenic chimeras in which antigenic sites are expressed in a fully functional manner will make it possible to analyse the immune response to poliovirus in terms of the individual sites. The reasons for the antigenic stability of poliovirus are not known, but possibly may be approached by examining the growth of antigenic chimeras and the ease with which antigenic variants resistant to polyclonal sera may be obtained. These studies are in progress.
